Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B‐Selective NMDA Receptor Antagonists with a Benzo[7]annulen‐7‐amine Scaffold
- 27 July 2017
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 12 (15), 1212-1222
- https://doi.org/10.1002/cmdc.201700311
Abstract
Antagonists that selectively target GluN2B-subunit-containing N-methyl-d-aspartate (NMDA) receptors are of major interest for the treatment of various neurological disorders. In this study, relationships between variously substituted benzo[7]annulen-7-amines and their GluN2B affinity were investigated. 2-Nitro-5,6,8,9-tetrahydrobenzo[7]annulen-7-one (8) represents the central building block for the introduction of various substituents at the 2-position and various 7-amino moieties. N-(3-Phenylpropyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amines with a 2-NO2 (7 c), 2-Cl (15 c), or 2-OBn group (22 c) show very high GluN2B affinity (Ki=1.6–3.6 nm). Docking studies revealed the same binding poses for benzo[7]annulen-7-amines and ifenprodil at the interface of GluN1b and GluN2B subunits. The large 2-OBn moiety of 22 c occupies a previously unrecognized subpocket, which explains its high GluN2B affinity (Ki=3.6 nm). In two-electrode voltage clamp experiments and cytoprotection assays, the high-affinity GluN2B ligands 7 c, 15 c, and 22 c could not inhibit the glutamate-/glycine-evoked current and cytotoxic effects. However, the analogous phenols 16 c ((3-phenylpropyl)amino moiety) and 16 d ((4-phenylbutyl)amino moiety) with 10-fold lower GluN2B affinity (Ki=28 and 21 nm, respectively) showed promising inhibition of glutamate-/glycine-evoked effects in both assays. The presence of a phenolic hydroxy group seems to be essential for inducing conformational changes of the receptor protein, which finally results in closure of the ion conduction pathway.Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 29 references indexed in Scilit:
- Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptorsNature, 2011
- Molecular basis of NMDA receptor functional diversityEuropean Journal of Neuroscience, 2011
- Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diolsBioorganic & Medicinal Chemistry, 2010
- Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonistsBioorganic & Medicinal Chemistry, 2010
- Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptorsJournal of Pharmaceutical and Biomedical Analysis, 2010
- Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potentialBritish Journal of Pharmacology, 2009
- NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death BothIn VitroandIn VivoJournal of Neuroscience, 2007
- Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological ApproachJournal of Neuroscience, 2006
- Subunit arrangement and function in NMDA receptorsNature, 2005
- NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian ratsNeuropharmacology, 2004